StonvexLoading…
StonvexStonvexStonvexCore line items from TXRH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-30 | Q3 2025 2025-09-30 | Q3 2025 2025-07-01 |
|---|---|---|---|---|
Revenue | $1.63B | $5.88B | $4.40B | $2.96B |
Operating Income | $146.34M | $474.74M | $378.02M | $281.07M |
Net Income | $126.00M | $414.33M | $327.65M | $242.75M |
EPS (Diluted) | $1.87 | $6.10 | $4.82 | $3.57 |
Total Assets | $3.57B | $3.55B | $3.27B | $3.26B |
Total Liabilities | $2.04B | $2.07B | $1.79B | $1.79B |
Cash & Equivalents | $214.56M | $134.71M | $108.17M | $176.80M |
Free Cash Flow OCF − CapEx | $178.91M | $342.07M | $210.79M | $196.07M |
Shares Outstanding | 65.83M | 65.94M | 66.23M | 66.45M |